Castle Biosciences, Inc.Castle Biosciences, Inc.Castle Biosciences, Inc.

Castle Biosciences, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪632.76 M‬USD
‪−57.47 M‬USD
‪219.79 M‬USD
‪25.08 M‬
Beta (1Y)

About Castle Biosciences, Inc.

Derek J. Maetzold
Employees (FY)
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CSTL is 22.82 USD — it has decreased by 0.44% in the past 24 hours. Watch Castle Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Castle Biosciences, Inc. stocks are traded under the ticker CSTL.
CSTL stock has fallen by 0.26% compared to the previous week, the month change is a 6.40% fall, over the last year Castle Biosciences, Inc. has showed a 68.91% increase.
We've gathered analysts' opinions on Castle Biosciences, Inc. future price: according to them, CSTL price has a max estimate of 40.00 USD and a min estimate of 28.00 USD. Watch CSTL chart and read a more detailed Castle Biosciences, Inc. stock forecast: see what analysts think of Castle Biosciences, Inc. and suggest that you do with its stocks.
CSTL reached its all-time high on Feb 10, 2021 with the price of 107.69 USD, and its all-time low was 9.26 USD and was reached on Jun 5, 2023. View more price dynamics on CSTL chart.
See other stocks reaching their highest and lowest prices.
CSTL stock is 3.68% volatile and has beta coefficient of 1.07. Track Castle Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Castle Biosciences, Inc. there?
Today Castle Biosciences, Inc. has the market capitalization of ‪632.76 M‬, it has decreased by 2.03% over the last week.
Yes, you can track Castle Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Castle Biosciences, Inc. is going to release the next earnings report on Aug 5, 2024. Keep track of upcoming events with our Earnings Calendar.
CSTL earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.33 USD resulting in a 72.90% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Castle Biosciences, Inc. earnings.
Castle Biosciences, Inc. revenue for the last quarter amounts to ‪71.32 M‬ USD, despite the estimated figure of ‪66.55 M‬ USD. In the next quarter, revenue is expected to reach ‪68.92 M‬ USD.
CSTL net income for the last quarter is ‪−2.53 M‬ USD, while the quarter before that showed ‪−2.58 M‬ USD of net income which accounts for 1.78% change. Track more Castle Biosciences, Inc. financial stats to get the full picture.
No, CSTL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 18, 2024, the company has 610.00 employees. See our rating of the largest employees — is Castle Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Castle Biosciences, Inc. EBITDA is ‪−29.15 M‬ USD, and current EBITDA margin is −25.32%. See more stats in Castle Biosciences, Inc. financial statements.
Like other stocks, CSTL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Castle Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Castle Biosciences, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Castle Biosciences, Inc. stock shows the sell signal. See more of Castle Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.